Natera chief legal officer Daniel Rabinowitz sells $4.57m stock
Daniel Rabinowitz, Natera Inc.'s Chief Legal Officer, sold 16,800 shares of company stock for approximately $4.57 million on July 1, 2026. This sale was conducted under a Rule 10b5-1 trading plan adopted in December 2025, leaving him with 172,294 shares. The transaction occurred while Natera's stock was near its 52-week high, with InvestingPro indicating it might be overvalued despite recent positive news regarding its Signatera test approvals and analyst optimism.
Natera (NTRA) legal chief sells 16,800 shares under Rule 10b5-1 plan
Daniel Rabinowitz, the Secretary and Chief Legal Officer of Natera, Inc. (NTRA), sold 16,800 shares of common stock through 12 separate open-market transactions on July 1, 2026. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. The shares were sold at weighted-average prices ranging from approximately $266.33 to $278.78 per share, totaling over $4.5 million, and this disclosure does not alter the company's fundamentals.
Natera (NTRA) president sells 3,000 shares under Rule 10b5-1 trading plan
Solomon Moshkevich, President of Clinical Diagnostics at Natera (NTRA), reported selling 3,000 shares of common stock on July 1, 2026. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2024. The shares were sold in open-market transactions at weighted average prices ranging from approximately $267.19 to $274.06 per share, with Moshkevich retaining a significant direct equity stake in Natera.
Form 4 Natera Inc For: 6 July By Investing.com
This article reports on a Form 4 filing for Natera Inc. (NTRA) on July 6. Form 4s are SEC filings used to disclose changes in beneficial ownership of securities by company insiders. The content is brief and primarily focuses on the filing announcement, with no further details about the transaction itself.
Natera chief legal officer Daniel Rabinowitz sells $4.57m stock By Investing.com
Natera's Chief Legal Officer, Daniel Rabinowitz, sold 16,800 shares of company stock totaling approximately $4.57 million on July 1, 2026, through a pre-arranged trading plan. This sale occurred while Natera's stock is near its 52-week high and is considered overvalued according to InvestingPro analysis, despite the company's recent positive developments in cancer diagnostics.
Board member Monica Bertagnolli exits Natera (NASDAQ: NTRA)
Monica Bertagnolli has resigned from Natera's Board of Directors and all associated committees, effective July 1, 2026. Her departure is attributed to a new position at the National Academy of Medicine and is not due to any disagreements with the company's operations, policies, or practices. This information was disclosed in an 8-K filing by Natera, Inc.
Natera publishes Signatera survival data in JAMA Oncology
Natera (NASDAQ:NTRA) has published new data in JAMA Oncology on its Signatera molecular residual disease (MRD) test for colorectal liver metastases patients. The study, which included 298 patients from the GALAXY trial, found that MRD-positive patients benefited significantly from adjuvant chemotherapy after surgery, while MRD-negative patients did not show additional survival benefit from such treatment. These findings suggest that Signatera could help personalize oncology treatment decisions by identifying patients most likely to benefit from adjuvant chemotherapy.
Natera study shows MRD test predicts chemo benefit in liver cancer
A Natera study published in JAMA Oncology demonstrates that its Signatera molecular residual disease (MRD) test can predict the benefit of adjuvant chemotherapy in patients with resected colorectal liver metastases, particularly those who are MRD-positive post-surgery. This finding could help identify patients who would benefit most from chemotherapy, improving disease-free and overall survival rates. The company's stock has shown strong performance, reflecting investor confidence, and Signatera recently received regulatory approval in Japan for colorectal cancer.
Natera, Inc. (NTRA) Stock Analysis: Navigating Growth Amidst Challenging Valuations
Natera, Inc. (NTRA), a leader in diagnostics and research, shows robust revenue growth but faces challenges with profitability and valuation, reflected in a negative forward P/E ratio. Despite strong analyst support and strategic partnerships, its high valuation and lack of dividends warrant cautious consideration for investors. The company's ability to translate revenue into sustainable earnings will be crucial for its future stock performance.
Natera Inc focuses on genetic testing growth as investors watch Nasdaq trading
Natera Inc, a Nasdaq-listed genetic testing specialist (NTRA, US6323071042), continues to expand its diagnostics platform, focusing on molecular diagnostics and cell-free DNA analysis for clinical decision-making. The company's business model relies on genetic testing services, R&D, and collaborations, generating revenue per-test with a focus on reimbursement. Investors track the stock's performance, which is influenced by future test volumes, reimbursement stability, and research progress, reflecting the inherently volatile yet growth-oriented life sciences sector.
Natera (NTRA) Lands New Trial Partnerships, Is The Upside Already Priced In?
Natera (NTRA) has secured new trial partnerships and regulatory approval for its Signatera test in Japan, leading to significant stock momentum with a 31.30% return in 30 days and 72.68% over one year. While a popular valuation narrative suggests the stock is 7% overvalued at $279.32 against a fair value of $260.05, Simply Wall St's DCF model indicates a 49% undervaluation, suggesting potential upside at an estimated $543.40. Investors are encouraged to assess both viewpoints and underlying assumptions.
NTRA - Natera Inc Options
This article provides a detailed financial overview of Natera Inc. (NTRA), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights the company's valuation ratios, growth rates, and market indicators as of July 2, 2024.
Natera stock hits all-time high at $279.63
Natera Inc. stock has reached an all-time high of $279.63, reflecting a 71.25% increase over the past year and a $39.8 billion market cap. This significant performance is bolstered by recent positive developments including a partnership with Aveta Biomics for a Phase 3 clinical trial, regulatory approval for its Signatera test in Japan, and upgraded analyst ratings. Despite its all-time high, some analysis suggests the stock might be overvalued at current levels.
Why Natera (NTRA) Is Up 6.3% After New Signatera Cancer Trial And Japan Launch Milestones
Natera (NTRA) saw its stock rise by 6.3% following significant announcements, including the integration of its Signatera MRD test into a global Phase 3 head and neck cancer trial, expansion of Prospera's role in kidney transplant studies, and PMDA approval for Signatera in colorectal cancer in Japan. These developments are expected to deepen Natera’s involvement in clinical programs and international care guidelines, potentially enhancing the adoption of its oncology and transplant testing platforms. The Japan approval, especially, offers a concrete path to market use in a major colorectal cancer population by late 2026, though investors are also weighing potential risks from rising R&D and legal costs.
Director Solomon Moshkevich reports share sales (NTRA)
Natera, Inc. Director Solomon Moshkevich filed a Form 144 detailing proposed and recent sales of Common Stock. The filing indicates a proposed sale of 3,000 performance shares and lists multiple sales transactions that occurred between April 28, 2026, and June 1, 2026, with associated gross proceeds. The document also provides contextual information on the total outstanding shares and key terms related to the filing.
Insider 10b5-1 sales reported for NTRA (NTRA) including 33,600 shares
A Form 144 filing for Natera, Inc. (NTRA) indicates proposed insider sales of Common Stock, including a 10b5-1 sale of 33,600 shares for over $8.4 million on June 24, 2026. The filing also details smaller 10b5-1 transactions from April and May 2026, and references 16,800 shares from previously exercised options in January 2022. These are routine notifications for scheduled insider dispositions, with Daniel Rabinowitz identified as the reporting person.
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
Natera (NTRA) has partnered with Aveta Biomics to integrate its Signatera test into AVTA 30-01, a global Phase 3 trial for APG-157 in head and neck squamous cell carcinoma. This collaboration aims to assess molecular residual disease (MRD) and treatment response, further validating Signatera's potential in precision oncology. The partnership is expected to strengthen Natera's position and explore more biopharma collaborations for MRD-guided treatments.
Roelof Botha of Natera (NTRA) granted RSUs and reports over 1.08M shares
Natera director Roelof Botha was granted 1,571 Restricted Stock Units (RSUs) vesting in June 2027, along with an additional 120 fully vested RSUs in lieu of quarterly board retainer fees. These grants are a small fraction of his total holdings, which include 4,585 direct shares and over 1.07 million shares held indirectly through estate planning vehicles. The filing underscores his ongoing equity compensation and significant indirect ownership in Natera.
Enterprise value to EBIT forward of Natera, Inc. – NASDAQ:NTRA
The article focuses on the enterprise value to EBIT forward for Natera, Inc. (NASDAQ: NTRA). It appears to be an entry on a financial data platform providing this specific metric for the company. The rest of the content consists of general navigation, disclaimers, and product offerings of the financial platform.
Form 4 Natera Inc For: 30 June By Investing.com
This article reports on a Form 4 filing by Natera Inc. (NTRA) for June 30, as released by Investing.com. It is a brief announcement indicating the availability of the regulatory filing. The symbol NTRA is noted to be up 1.23%.
Natera (NTRA) director Monica Bertagnolli receives RSU grants for board service
Natera director Monica Bertagnolli has been granted 75 restricted stock units (RSUs) that will vest on June 11, 2027, or sooner if the company undergoes a change in control. She also received an additional 1,571 RSUs, fully vested upon issuance, in lieu of a $16,875 quarterly board retainer fee. These grants represent equity-based compensation, with each RSU equivalent to one share of Natera common stock, and are not open-market purchases.
Natera (NTRA) director awarded $425K in RSUs vesting from 2027
Natera, Inc. director Thomas J. Lynch Jr. was granted 1,905 Restricted Stock Units (RSUs) valued at $425,000. These RSUs will vest in three equal annual installments starting on June 2, 2027. This equity compensation grant brings his directly held shares to 1,905 (after accounting for the RSUs).
Natera (NTRA) director receives 1,674 RSUs in equity compensation grants
Natera, Inc. director Rowan E. Chapman has received 1,674 restricted stock units (RSUs) as equity compensation. This includes 103 RSUs that will vest on June 11, 2027, and 1,571 RSUs issued in lieu of quarterly board retainer fees, which were fully vested at issuance. These grants increase the director's potential future share ownership in Natera.
Natera (NTRA) director granted fully vested RSUs instead of cash fees
Natera, Inc. director Eric H. Rubin was granted 75 fully vested Restricted Stock Units (RSUs) of Common Stock as part of his board compensation, replacing his quarterly retainer fees of $16,875. Following this transaction, Rubin directly holds 2,204 shares of Natera common stock. Each RSU represents a contingent right to receive one share of the company's common stock.
Natera (NTRA) director granted RSUs instead of cash board fees
Natera, Inc. director Marcus Gail Boxer recently received two Restricted Stock Unit (RSU) awards. One award consisted of 98 RSUs vesting on June 11, 2027, with accelerated vesting upon a change in control. The other award was for 1,571 RSUs, fully vested upon issuance, granted in lieu of a $21,875 quarterly cash retainer for his board service.
[Form 4] Natera, Inc. Insider Trading Activity
Natera, Inc. director Herm Rosenman reported two equity compensation awards in the form of restricted stock units (RSUs). One grant for 1,571 shares vests on June 11, 2027, or earlier upon a change in control, while another for 106 shares was fully vested upon issuance in lieu of quarterly board retainer fees. These transactions indicate stock-based compensation rather than open-market purchases.
Natera Stock 5-Day Winning Spree: Stock Climbs 19%
Natera stock has experienced a significant 5-day winning streak, resulting in a 19% climb. The article title highlights this recent positive performance for the company's shares.
3 Stocks Estimated To Be Trading At A Discount Of Up To 48.9%
The article highlights three US stocks—Natera (NTRA), Pattern Group (PTRN), and AbbVie (ABBV)—that are estimated to be trading significantly below their fair value based on discounted cash flow analysis. Each company's operations, estimated discount, and growth prospects are detailed, suggesting potential undervaluation despite various financial considerations like debt and insider trading. The analysis is framed within a broader market context of growth and the advantage of identifying undervalued stocks.
Price to sales forward of Natera, Inc. – NASDAQ:NTRA
This article provides financial information for Natera, Inc. (NASDAQ: NTRA), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of the crawl, with no trades reported. The content is presented within the context of TradingView's platform, offering financial data and tools for investors.
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
Natera and Aveta Biomics have formed a strategic partnership for Aveta's global Phase 3 registrational trial (AVTA 30-01) of APG-157 in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Natera's Signatera™ test will be used as a secondary endpoint to evaluate molecular response and assess molecular residual disease (MRD) throughout the trial. This collaboration aims to advance treatment for LA-HNSCC patients by leveraging APG-157's potential to activate anti-tumor immunity and Signatera's ability to detect recurrence earlier.
Exploring 3 High Growth Tech Stocks in the US Market
The US market has seen a 2.5% drop in the last week but is up 19% over the past year, with earnings projected to grow 18% annually. This article highlights three high-growth tech stocks—Natera (NTRA), Shopify (SHOP), and Workday (WDAY)—that demonstrate strong innovation and scalability to capitalize on these promising forecasts. Each company's recent achievements, strategic partnerships, and financial strength are detailed as factors contributing to their growth potential.
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
Natera and Aveta Biomics have formed a strategic partnership for Aveta's global Phase 3 clinical trial (AVTA 30-01) of APG-157, an oral immunotherapy for locally advanced head and neck squamous cell carcinoma. The trial will enroll approximately 826 patients and incorporate Natera's Signatera testing to assess molecular residual disease (MRD) and treatment response, aiming to validate ctDNA findings and improve understanding of treatment benefits. APG-157 has received FDA Fast Track and Orphan Drug Designations for this indication.
Natera joins Aveta's global Phase 3 head and neck cancer trial
Natera and Aveta Biomics have formed a strategic partnership for Aveta's global Phase 3 clinical trial (AVTA 30-01) evaluating APG-157 in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Natera's Signatera™ molecular residual disease (MRD) testing will be integrated into the trial as a secondary endpoint to assess molecular response and treatment effectiveness. APG-157 has received FDA Fast Track and Orphan Drug Designations, and the trial is expected to begin enrollment in the second half of 2026.
Price to book forward of Natera, Inc. – NASDAQ:NTRA
This article provides a financial data point, specifically the "Price to book forward" for Natera, Inc. (NASDAQ: NTRA). It indicates the value for this metric and is presented within the context of TradingView's financial analysis tools. The content is primarily a data placeholder rather than an in-depth financial report.
U.S. Supreme Court Rejects CareDxA’s Appeal in Natera, Inc. (NTRA) False-advertising Dispute
The U.S. Supreme Court has declined to hear CareDx's appeal in its false-advertising dispute with Natera, Inc. (NTRA), leaving lower court rulings intact. These rulings denied CareDx damages regarding claims about kidney transplant tests, despite a jury finding of false advertising. Natera expressed satisfaction with the decision, while CareDx had argued for presumed deception in cases of "deliberately false" advertising.
Insider Sell Alert: Herm Rosenman Sells 16,530 Shares of Natera Inc (NTRA)
Herm Rosenman, a Director at Natera Inc (NTRA), sold 16,530 shares of the company on June 24, 2026, reducing his holdings to 4,250 shares. This transaction is part of a trend of insider selling at Natera, with 129 insider sells and no buys over the past year. Natera's stock is currently trading at $250, making it modestly overvalued according to its GF Value of $202.36.
Natera, Inc. Actuals & Estimates (NASDAQ:NTRA)
This article provides an in-depth financial overview of Natera, Inc. (NTRA), including current stock price, historical performance, analyst forecasts, and various financial metrics. It details earnings, revenue, market capitalization, and volatility, offering insights for potential investors.
Form 4 Natera Inc For: 26 June By Investing.com
This article from Investing.com reports that a Form 4 filing for Natera Inc. was submitted on June 26. The brief piece contains only this information, alongside a stock quote for NTRA and general market data. It primarily serves as a placeholder announcement for the regulatory filing.
Natera (NTRA) chief legal officer sells 33,600 shares in pre-set 10b5-1 trades
Natera, Inc.'s Chief Legal Officer, Daniel Rabinowitz, sold 33,600 shares of common stock on June 24, 2026, through a pre-arranged Rule 10b5-1 trading plan. The sales occurred at weighted average prices between approximately $250 and $253 per share. Following these transactions, Rabinowitz retains a direct holding of 189,094 shares of Natera Common Stock.
Natera (NTRA) director’s 10b5-1 sale leaves 4,250 shares
Natera director Herm Rosenman sold 16,530 shares of NTRA common stock at $250.00 per share on June 24, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. This transaction, totaling $4.13 million, leaves him with 4,250 shares directly held. The sale was reported in a Form 4 filing and is categorized with a "Very High" impact and "Negative" sentiment.
Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial
Natera has partnered with Eledon Pharmaceuticals to integrate its Prospera test into a global Phase 3 kidney transplant trial. Prospera will be the exclusive molecular monitoring assay for longitudinal surveillance in the trial, which focuses on a new immunosuppression therapy. This collaboration enhances Natera's position in transplant diagnostics and could lead to increased physician familiarity and future adoption of Prospera in routine kidney transplant care.
Natera (NTRA) Receives Outperform Rating and $310 Target from Bernstein Analyst
Bernstein analyst Eve Burstein reinstated coverage of Natera Inc (NTRA) with an Outperform rating and a $310 price target, signaling renewed optimism in the life science tools and diagnostics sector. Natera, with a market cap of $37.34 billion and a GF Score of 79, is well-positioned for growth, especially with its impressive growth rank of 10/10. However, investors should also consider the company's profitability challenges (profitability rank of 3/10) and significant insider selling without corresponding insider buying.
Banu Saritas-Yildirim: Signatera is Approved in Japan by FDA
Banu Saritas-Yildirim, Senior Director of Regulatory Affairs at Natera Inc., announced on LinkedIn that Signatera has received approval in Japan, following its FDA approval in May. This development is significant for Japanese colorectal cancer patients, as it will enhance physicians' ability to assess chemotherapy benefits and monitor for recurrence. Saritas-Yildirim credited Tiffany Hsueh for leading the project and thanked the PMDA review team, MHLW, and GALAXY clinical trial participants.
Eledon Teams Up With Natera on Phase 3 Study
Eledon Pharmaceuticals is partnering with Natera for its upcoming Phase 3 clinical trial evaluating tegoprubart, an investigational therapy to prevent organ rejection in kidney transplantation. The trial will utilize Natera’s Prospera kidney transplant assessment test to monitor for rejection. The Irvine-based biotech company expects to enroll approximately 600 patients in the trial, which is scheduled to begin later this year.
[144] Natera, Inc. SEC Filing
This article details a Form 144 SEC filing by Natera, Inc. (NTRA) concerning proposed sales of securities by Daniel Rabinowitz. The filing reports recent 10b5-1 dispositions of common stock totaling over 10,000 shares for more than $2 million and lists Restricted Stock Units and previously exercised stock options as securities available for sale. It provides key figures and insights into the regulatory nature of Form 144 and 10b5-1 sales.
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar?
Natera (NTRA) stock surged 10.7% due to optimism surrounding the approval of its Signatera test in Japan for colorectal cancer. While the company's revenue is projected to increase, its earnings per share estimate has been revised slightly lower, indicating potential headwinds. Investors should monitor Natera's future performance to see if the recent gains can be sustained.
Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial
Natera and Eledon Therapeutics have announced a strategic partnership for the use of Natera's Prospera™ monitoring in a planned Phase 3 kidney transplant trial. This collaboration will likely focus on improving patient outcomes through advanced monitoring techniques during the trial. The announcement suggests a move towards integrating specialized diagnostic tools into clinical research for transplant patients.
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
Natera and Eledon Pharmaceuticals have announced a strategic partnership for Natera's Prospera kidney transplant assessment test to be exclusively used in Eledon's planned Phase 3 clinical trial of tegoprubart. This trial aims to prevent organ rejection in kidney transplantation, with enrollment expecting to include approximately 600 kidney transplant recipients globally. The collaboration marks the first time Prospera will be incorporated as a longitudinal surveillance tool in a large-scale therapeutic clinical trial, providing insights into allograft health and the impact of the investigational immunosuppression regimen.
ETFs Investing in Natera, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold Natera, Inc. stocks, providing detailed financial information for each. The data includes market value, weight of Natera in the fund, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The ETFs listed cover diverse investment strategies and market capitalizations, offering insights for investors interested in Natera, Inc. through diversified funds.
[144] Natera, Inc. SEC Filing
This SEC Form 144 filing indicates a proposed sale of 16,530 shares of Natera, Inc. (NTRA) common stock by an individual through Morgan Stanley Smith Barney LLC, with an aggregate market value of $4,132,500. The shares were acquired on June 24, 2026, through a stock option exercise, with payment made in cash. The filing includes standard disclosures required by Rule 144 of the Securities Act of 1933.
